Search clinical trials for: TAK-951

Total 5146 results

Takeda

Completed

Phase 1, TAK-648, Single-Rising Dose Study

Healthy Volunteers
AbbVie

Completed

A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

Parkinson's Disease (PD)

United States
Takeda

Completed

A Study of TAK-510 in Healthy Adults

Healthy Participants

United States
Calithera Biosciences, Inc

Withdrawn

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

Advanced Solid Neoplasms | Lymphoma Neoplasms
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

Healthy Volunteers

United States
Takeda

Recruiting

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Takeda

Recruiting

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

Narcolepsy Type 1 | Narcolepsy Type 2

Spain, Germany, United States, Italy, Netherlands, Japan, France, Norway, Australia, Finland, Switzerland, Sweden
Takeda
Takeda Development Center Americas, Inc.

Recruiting

First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer

Unresectable Locally Advanced or Metastatic Cancer

Spain, United States, Australia, Canada
Takeda

Active, not recruiting

A Study of TAK-102 in Adult With Previously-Treated Solid Tumors

Solid Tumors

Japan
Takeda

Completed

A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Coronavirus Disease (COVID-19)

Japan
Calithera Biosciences, Inc

Withdrawn

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

Lymphoma, Malignant | Advanced Solid Neoplasms

United States
Calithera Biosciences, Inc

Terminated

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

Lymphoma, Non-Hodgkin | Lymphoma, Follicular, Marginal Zone

Korea, Republic of, Japan
Calithera Biosciences, Inc

Terminated

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States, Canada
Millennium Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

Prostate Cancer

United States
Millennium Pharmaceuticals, Inc.

Terminated

Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies

Advanced Nonhematological Malignancies

United States
Takeda

Completed

Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis

Erosive Esophagitis

Japan
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Advanced Metastatic Melanoma | Advanced Non-hematologic Malignancies

United States
Takeda

Terminated

Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy

Diabetic Neuropathies
Millennium Pharmaceuticals, Inc.

Completed

Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies

Advanced Solid Tumors

United States
Takeda

Completed

Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2
Millennium Pharmaceuticals, Inc.

Completed

Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer

Solid Tumors

United States
Takeda

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

Healthy Volunteers

United States
Takeda

Terminated

Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone

Low Testosterone

United States
Takeda

Completed

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants

Autoimmune Disease

United Kingdom
T3D Therapeutics, Inc.
National Institute on Aging (NIA); Alzheimer's Association; Clinilabs, Inc.

Completed

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

Alzheimer Disease

United States
Millennium Pharmaceuticals, Inc.

Completed

A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer

Cancer

United States
AVEO Pharmaceuticals, Inc.

Completed

A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma

Carcinoma, Renal Cell

Ukraine, India, Russian Federation
AbbVie

Completed

Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease

Parkinson's Disease

United States
Takeda

Completed

A Study of TAK-861 in Participants With Narcolepsy Type 2

Narcolepsy Type 2

Spain, United States, Japan, Italy, France, Germany, Australia, Netherlands, Finland, Norway, Sweden, Switzerland
Takeda

Completed

Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy

Healthy Participants and Patients With Narcolepsy

Japan
Takeda

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants

Healthy Volunteers

United States
Takeda
Ovid Therapeutics Inc.

Completed

Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies

Developmental and/or Epileptic Encephalopathies

United States
Takeda

Completed

Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy

Diabetic Neuropathies

United States, Canada
Takeda

Completed

Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Participants

Ascending Single Dose Study
Takeda

Completed

Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease

Non-erosive Gastroesophageal Reflux Disease

Japan
Takeda

Terminated

Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus
Takeda

Recruiting

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States
Takeda

Not yet recruiting

A Study of TAK-279 in Healthy Chinese Adults

Healthy Volunteers

China
Bradley A. McGregor, MD
Calithera Biosciences, Inc

Completed

Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Takeda

Completed

A Study of Soticlestat Tablets in Healthy Adults

Healthy Volunteers

United States
Takeda

Active, not recruiting

A Study of Soticlestat in Adults and Children With Rare Epilepsies (Endymion 1)

Epilepsy | Dravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)

United States, Canada, Australia, China, Israel, Poland, Spain, Portugal
Takeda

Terminated

A Study of TAK-994 in Adults With Narcolepsy

Narcolepsy Type 1 (NT 1)

United States, Italy, Finland, Canada, Hungary, Czechia, France, Japan, Korea, Republic of, Spain
Takeda

Completed

A Study of TAK-919 in Healthy Japanese Adults (COVID-19)

Coronavirus Disease (COVID-19)

Japan
Neurocrine Biosciences
Takeda

Completed

Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects

Healthy Volunteers

Japan
Millennium Pharmaceuticals, Inc.

Completed

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Melanoma | Solid Tumor | Metastatic Melanoma | Neoplasm

United States, United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

Obstructive Sleep Apnea

United States
Millennium Pharmaceuticals, Inc.

Terminated

A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

Advanced Malignant Solid Tumors

United States
Takeda

Completed

A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects

Clinical Pharmacology

Japan
Takeda

Completed

Double-blind Comparative Study of TAK-875

Diabetes Mellitus

Japan
Takeda

Completed

Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia

Neuralgia, Postherpetic

Poland, United Kingdom, Germany, Bulgaria, Australia, Netherlands, Russian Federation, Czech Republic, South Africa

3

Subscribe